Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
Frequently asked questions
What sector does Isofol Medical AB (ISOFOL) operate in?
Isofol Medical AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Isofol Medical AB (ISOFOL) current stock price?
As of the latest data, Isofol Medical AB stock price is SEK 0.88, with a previous close of SEK 0.89. Isofol Medical AB lost -SEK 0.02 in the last trading session, representing a -1.68% loss.
What is Isofol Medical AB (ISOFOL) current market capitalization?
Isofol Medical AB market cap is approximately 281.39 million.
What is Isofol Medical AB (ISOFOL) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.22, and the forward EPS is -SEK 0.03.
What is Isofol Medical AB (ISOFOL) EBITDA?
Isofol Medical AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.76 million.
Does Isofol Medical AB (ISOFOL) pay dividends?
No. Isofol Medical AB does not pay a dividend.
What is Isofol Medical AB (ISOFOL) beta (volatility) score?
Isofol Medical AB has a beta of 1.027, meaning its volatility is roughly in line with the market.